Skip to content

US · MDCX · BIOTECHNOLOGY

Medicus Pharma Ltd. Common Stock (MDCX) intrinsic value and stock valuation

$1.14as of 2026-11-21 · Mkt cap 6.54M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medicus Pharma Ltd. Common Stock DCF and intrinsic value

InvestorsCraft values MDCX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MDCX’s statements →

Medicus Pharma Ltd. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Conshohocken, PA 19428 medicuspharma.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-25.37M
20212025
Free cash flow
-$-22.78M
20212025
Total equity
$40K
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-18.35M-$-11.18M-$-4.73M-$-980K-$-1.44M
Net income-$-25.37M-$-11.16M-$-5.31M-$-1.69M-$-2.06M
EPSd-$-1.47M-$-1.16M-$-1.06M-$-209.94K-$-255.9K
Operating cash flow-$-22.78M-$-10.25M-$-4.16M-$-1.06M-$-1.45M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-22.78M-$-10.25M-$-4.16M-$-1.06M-$-1.45M
Total assets$10.1M$5.65M$1.89M$280K$80K
Total debt$4M$320K$0.00$1.53M$670K
Net debt-$-4.71M-$-3.84M-$-1.72M$1.26M$590K
Total equity$40K$3.13M$1.11M-$-12.2M-$-10.51M
Cash and short-term investments$8.71M$4.16M$1.72M$270K$80K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$7.72M$3.53M$190K$650K$1.18M
Selling, general and administrative expenses$17.9M$7.65M$2.46M$330K$260K
Other expenses-$-7.29M$0.00$2.07M$0.00$0.00
Operating expenses$18.4M$11.2M$4.73M$980K$1.44M
Cost and expenses$18.4M$11.2M$4.73M$980K$1.44M
Interest income$0.00$100K$10K-$-580K-$-580K
Interest expense$140K$320K$600K$530K$120K
Depreciation and amortization$0.00$0.00$2.07M$0.00$0.00
Ebitda-$-25.23M-$-11.16M-$-590K-$-1.17M-$-1.94M
Operating income-$-18.35M-$-11.18M-$-4.73M-$-980K-$-1.44M
Total other income/expenses, net-$-7.02M$30K-$-580K-$-710K-$-610K
Income before tax-$-25.37M-$-11.16M-$-5.31M-$-1.69M-$-2.06M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-25.37M-$-11.16M-$-5.31M-$-1.69M-$-2.06M
Weighted average shares outstanding$17.3M$9.62M$3.48M$1.93M$8.05M
Weighted average diluted shares outstanding$17.3M$9.62M$5.03M$8.05M$8.05M
Balance sheet
20252024202320222021
Cash and short-term investments$8.71M$4.16M$1.72M$270K$80K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.89M$5.38M$1.89M$280K$80K
Property, plant and equipment, net$170K$270K$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$170K$270K$0.00$0.00$0.00
Total assets$10.1M$5.65M$1.89M$280K$80K
Accounts payable$3.44M$1.28M$210K$0.00$0.00
Short-term debt$3.93M$120K$0.00$1.53M$670K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.94M$2.31M$780K$12.5M$10.6M
Long-term debt$60K$210K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$60K$210K$0.00$0.00$0.00
Capital lease obligations$40K$210K$0.00$0.00$0.00
Total liabilities$10M$2.51M$780K$12.5M$10.6M
Common stock$57.1M$30.5M$18.8M$190K$190K
Retained earnings-$-64.35M-$-28.9M-$-17.75M-$-12.39M-$-10.7M
Accumulated other comprehensive income (loss)$10K$0.00$0.00$0.00$0.00
Total equity$40K$3.13M$1.11M-$-12.2M-$-10.51M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$4M$320K$0.00$1.53M$670K
Net debt-$-4.71M-$-3.84M-$-1.72M$1.26M$590K
Cash flow statement
20252024202320222021
Net income-$-35.44M-$-11.16M-$-5.31M-$-1.69M-$-2.06M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.51M$710K$100K$0.00$0.00
Change in working capital$410K$30K$470K-$-80K-$-10K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$810K$80K$0.00$0.00
Net cash provided by operating activities-$-22.78M-$-10.25M-$-4.16M-$-1.06M-$-1.45M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net-$-4.62M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-4.62M$0.00$0.00$0.00$0.00
Common stock issued$19.8M$7.52M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$31.9M$12.7M$5.61M$1.25M$880K
Net change in cash$4.54M$2.44M$1.45M$190K-$-570K
Cash at end of period$8.71M$4.16M$1.72M$270K$80K
Operating cash flow-$-22.78M-$-10.25M-$-4.16M-$-1.06M-$-1.45M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-22.78M-$-10.25M-$-4.16M-$-1.06M-$-1.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medicus Pharma Ltd. Common Stock

        Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

        CEO
        Raza Bokhari
        Employees
        16
        Beta
        -0.61

        Explore

        Frequently asked questions

        What is the intrinsic value of Medicus Pharma Ltd. Common Stock (MDCX)?

        InvestorsCraft does not currently publish an intrinsic value for MDCX. How the IC value is calculated.

        Is MDCX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MDCX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.